Prevagen is marketed as a memory supplement for age-related cognitive decline, but the evidence that it actually works is thin. The product’s single active ingredient, a protein called apoaequorin derived from jellyfish, has not been shown in independent research to improve memory or brain function. In fact, a federal court now prohibits the manufacturer from claiming it does.
What Prevagen Claims to Do
Prevagen is sold as a daily supplement in two strengths: Regular (10 mg of apoaequorin) and Extra Strength (20 mg). The manufacturer, Quincy Bioscience, has marketed it as a way to improve memory, sharpen thinking, and support overall brain health, particularly for adults experiencing normal age-related memory changes. It’s available over the counter as a capsule or chewable tablet.
The core idea behind the product is that apoaequorin, a calcium-binding protein originally found in a species of glowing jellyfish, can regulate calcium activity in brain cells and protect them from damage. That’s the theory. The reality is more complicated.
The Digestion Problem
The most fundamental scientific objection to Prevagen is simple: apoaequorin is a protein, and your body breaks down proteins during digestion. Stomach acid and digestive enzymes dismantle proteins into their component amino acids and small fragments long before they could reach the brain. The chance of an intact protein molecule surviving your gut, entering your bloodstream, and then crossing the blood-brain barrier is, as researchers at McGill University put it, “remote, to say the least.”
The manufacturer’s own unpublished safety research actually reinforces this point. That study found apoaequorin “is easily digested by pepsin,” the primary enzyme in your stomach. This was presented as evidence the protein is safe to eat, but it simultaneously undercuts the claim that it could reach the brain in a form that does anything useful. Many experts in neurology and pharmacology consider this a fatal flaw in the product’s premise.
What the Manufacturer’s Study Found
Prevagen’s marketing has leaned heavily on a single clinical trial called the Madison Memory Study, a 90-day, placebo-controlled trial involving 218 adults aged 40 to 91 who reported memory concerns. Participants took either 10 mg of apoaequorin daily or a placebo.
The headline numbers sound promising at first glance: a roughly 11% improvement in word recall and a nearly 16% improvement in delayed recall. But these results came with a significant caveat. They didn’t apply to the study group as a whole. The improvements appeared only in a subset of participants, specifically those with very mild cognitive concerns at the start. When you look at all participants together, the supplement didn’t outperform the placebo.
This matters because finding a benefit in a subgroup after a trial fails overall is a well-known statistical problem. If you slice data enough ways, some subgroup will appear to improve by chance alone. Harvard Health Publishing noted the real-world significance of these changes is uncertain and that the study’s own authors recommended further research. No additional high-quality, independent studies confirming these results have been published.
The FTC Lawsuit and Court Ruling
In 2017, the Federal Trade Commission and the New York state attorney general sued Quincy Bioscience for false advertising. The case went to a jury trial in 2024, where jurors found that many of the supplement’s claims were not supported by reliable evidence and that some were “materially misleading.”
In December 2024, after seven years of litigation, the FTC won the lawsuit. A court ordered Quincy Bioscience to stop making claims that Prevagen can improve brain function or memory. The FTC’s statement was blunt: the company had misled Americans concerned about memory loss.
This doesn’t mean Prevagen was pulled from shelves. Dietary supplements in the United States don’t require proof of effectiveness before being sold. The ruling only restricts what the company can say about the product in its advertising.
Known Side Effects
Prevagen is generally considered low-risk for most people, but reported side effects include headache, dizziness, nausea, difficulty sleeping, and anxiety. Ironically, memory problems are also listed among possible adverse effects. Combination products containing apoaequorin alongside other ingredients have been associated with blood pressure changes. The Merck Manual notes that the overall safety profile of apoaequorin is still not fully established.
Why People Still Buy It
Memory loss is genuinely frightening, and there are few easy solutions for it. Prevagen fills a gap that prescription medicine largely hasn’t: a simple, over-the-counter option that feels proactive. The supplement industry is built on this kind of hope, and Prevagen has been one of the best-selling brain supplements in the U.S. for years.
But the scientific picture is clear. The active ingredient is almost certainly digested before it reaches the brain. The only clinical trial supporting it showed benefits in a cherry-picked subgroup, was funded by the manufacturer, and has never been independently replicated. A federal court found the marketing claims misleading.
If you’re experiencing memory changes that concern you, the strategies with the strongest evidence behind them are not in a bottle. Regular aerobic exercise, consistent sleep, social engagement, and management of cardiovascular risk factors like high blood pressure and high cholesterol have all been linked to better cognitive outcomes in large, independent studies. These approaches address the actual biology of brain aging in ways a digested jellyfish protein cannot.